1887

Abstract

VIM-producing isolates are usually associated with high MICs to carbapenems. Preclinical studies investigating the pharmacokinetic–pharmacodynamic (PK-PD) characteristics of carbapenems against these isolates are lacking. The antibacterial activity of meropenem against one WT and three VIM-producing clinical isolates (median MICs 0.031, 8, 16 and 128 mg l) was studied in a dialysis-diffusion PK-PD model and verified in a thigh infection neutropenic animal model by testing selected strains and exposures. The PK-PD target associated with bactericidal activity was estimated and the target attainment for different dosing regimens was calculated with Monte Carlo analysis. The model was correlated with the data, with logCFU/ml reduction of < 1 for the VIM-producing (MIC 16 mg l) and >2 for the WT (MIC 0.031 mg l) isolates, with % T >MIC 25 and 100 %, respectively. The bactericidal activity for all isolates was associated with 40 %  T>MIC and attained in >90 % of cases with the standard 1 g q8 0.5 h infusion dosing regimen only for isolates with MICs up to 1 mg l. For isolates with MICs of 2–8 mg l, prolonged infusion regimens (4 h infusion q8 or 2 h infusion q4) of standard (1 g) and higher (2 g) doses or continuous infusion regimens (3–6 g) are required. For isolates with a MIC of 16 mg l the unconventional dosing regimen of 2 g as 2 h infusion q4 or 12 g continuous infusion will be required. Prolonged and continuous infusion regimens of meropenem may increase efficacy against VIM-producing isolates.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.000214
2016-03-01
2020-04-02
Loading full text...

Full text loading...

/deliver/fulltext/jmm/65/3/211.html?itemId=/content/journal/jmm/10.1099/jmm.0.000214&mimeType=html&fmt=ahah

References

  1. Ariano R. E., Nyhlén A., Donnelly J. P., Sitar D. S., Harding G.K.M., Zelenitsky S. A.. 2005; Pharmacokinetics and pharmacodynamics of meropenem in febrile neutropenic patients with bacteremia. Ann Pharmacother39:32–38 [CrossRef][PubMed]
    [Google Scholar]
  2. Binder L., Schwörer H., Hoppe S., Streit F., Neumann S., Beckmann A., Wachter R., Oellerich M., Walson P. D.. 2013; Pharmacokinetics of meropenem in critically ill patients with severe infections. Ther Drug Monit35:63–70 [CrossRef][PubMed]
    [Google Scholar]
  3. Bulik C. C., Christensen H., Li P., Sutherland C. A., Nicolau D. P., Kuti J. L.. 2010; Comparison of the activity of a human simulated, high-dose, prolonged infusion of meropenem against Klebsiella pneumoniae producing the KPC carbapenemase versus that against Pseudomonas aeruginosa in an in vitro pharmacodynamic model. Antimicrob Agents Chemother54:804–810 [CrossRef][PubMed]
    [Google Scholar]
  4. CLSI 2010; Performance Standards for Antimicrobial Susceptibility Testing; 20th Informational Supplement (June 2010 update) M100-S20-U. Wayne, PA, USA: Clinical and Laboratory Standards Institute;
  5. Cockcroft D. W., Gault M. H.. 1976; Prediction of creatinine clearance from serum creatinine. Nephron16:31–41 [CrossRef][PubMed]
    [Google Scholar]
  6. Daikos G. L., Panagiotakopoulou A., Tzelepi E., Loli A., Tzouvelekis L. S., Miriagou V.. 2007; Activity of imipenem against VIM-1 metallo-β-lactamase-producing Klebsiella pneumoniae in the murine thigh infection model. Clin Microbiol Infect13:202–205 [CrossRef][PubMed]
    [Google Scholar]
  7. Daikos G. L., Tsaousi S., Tzouvelekis L. S., Anyfantis I., Psichogiou M., Argyropoulou A., Stefanou I., Sypsa V., Miriagou V., other authors. 2014; Carbapenemase-producing Klebsiella pneumoniae bloodstream infections: lowering mortality by antibiotic combination schemes and the role of carbapenems. Antimicrob Agents Chemother58:2322–2328 [CrossRef][PubMed]
    [Google Scholar]
  8. DeRyke C. A., Banevicius M. A., Fan H. W., Nicolau D. P.. 2007; Bactericidal activities of meropenem and ertapenem against extended-spectrum-β-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model. Antimicrob Agents Chemother51:1481–1486 [CrossRef][PubMed]
    [Google Scholar]
  9. Fehér C., Rovira M., Soriano A., Esteve J., Martínez J. A., Marco F., Carreras E., Martínez C., Fernández-Avilés F., other authors. 2014; Effect of meropenem administration in extended infusion on the clinical outcome of febrile neutropenia: a retrospective observational study. J Antimicrob Chemother69:2556–2562 [CrossRef][PubMed]
    [Google Scholar]
  10. Giakkoupi P., Xanthaki A., Kanelopoulou M., Vlahaki A., Miriagou V., Kontou S., Papafraggas E., Malamou-Lada H., Tzouvelekis L. S., other authors. 2003; VIM-1 Metallo-β-lactamase-producing Klebsiella pneumoniae strains in Greek hospitals. J Clin Microbiol41:3893–3896 [CrossRef][PubMed]
    [Google Scholar]
  11. Jaruratanasirikul S., Sriwiriyajan S., Punyo J.. 2005; Comparison of the pharmacodynamics of meropenem in patients with ventilator-associated pneumonia following administration by 3-hour infusion or bolus injection. Antimicrob Agents Chemother49:1337–1339 [CrossRef][PubMed]
    [Google Scholar]
  12. Li C., Kuti J. L., Nightingale C. H., Nicolau D. P.. 2006; Population pharmacokinetic analysis and dosing regimen optimization of meropenem in adult patients. J Clin Pharmacol46:1171–1178 [CrossRef][PubMed]
    [Google Scholar]
  13. Li C., Du X., Kuti J. L., Nicolau D. P.. 2007; Clinical pharmacodynamics of meropenem in patients with lower respiratory tract infections. Antimicrob Agents Chemother51:1725–1730 [CrossRef][PubMed]
    [Google Scholar]
  14. Loli A., Tzouvelekis L. S., Tzelepi E., Carattoli A., Vatopoulos A. C., Tassios P. T., Miriagou V.. 2006; Sources of diversity of carbapenem resistance levels in Klebsiella pneumoniae carrying blaVIM-1. J Antimicrob Chemother58:669–672 [CrossRef][PubMed]
    [Google Scholar]
  15. Maglio D., Ong C., Banevicius M. A., Geng Q., Nightingale C. H., Nicolau D. P.. 2004; Determination of the in vivo pharmacodynamic profile of cefepime against extended-spectrum-beta-lactamase-producing Escherichia coli at various inocula. Antimicrob Agents Chemother48:1941–1947 [CrossRef][PubMed]
    [Google Scholar]
  16. Markogiannakis A., Tzouvelekis L. S., Psichogiou M., Petinaki E., Daikos G. L.. 2013; Confronting carbapenemase-producing Klebsiella pneumoniae. Future Microbiol8:1147–1161 [CrossRef][PubMed]
    [Google Scholar]
  17. Mattoes H. M., Kuti J. L., Drusano G. L., Nicolau D. P.. 2004; Optimizing antimicrobial pharmacodynamics: dosage strategies for meropenem. Clin Ther26:1187–1198 [CrossRef][PubMed]
    [Google Scholar]
  18. Meletiadis J., Al-Saigh R., Velegraki A., Walsh T. J., Roilides E., Zerva L.. 2012; Pharmacodynamic effects of simulated standard doses of antifungal drugs against Aspergillus species in a new in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother56:403–410 [CrossRef][PubMed]
    [Google Scholar]
  19. Nicolau D. P.. 2008; Pharmacokinetic and pharmacodynamic properties of meropenem. Clin Infect Dis47:(Suppl. 1)S32–S40 [CrossRef][PubMed]
    [Google Scholar]
  20. Pea F., Viale P., Cojutti P., Furlanut M.. 2012; Dosing nomograms for attaining optimum concentrations of meropenem by continuous infusion in critically ill patients with severe Gram-negative infections: a pharmacokinetics/pharmacodynamics-based approach. Antimicrob Agents Chemother56:6343–6348 [CrossRef][PubMed]
    [Google Scholar]
  21. Podschun R., Ullmann U.. 1998; Klebsiella spp. as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity factors. Clin Microbiol Rev11:589–603[PubMed]
    [Google Scholar]
  22. Siopi M., Mavridou E., Mouton J. W., Verweij P. E., Zerva L., Meletiadis J.. 2014; Susceptibility breakpoints and target values for therapeutic drug monitoring of voriconazole and Aspergillus fumigatus in an in vitro pharmacokinetic/pharmacodynamic model. J Antimicrob Chemother69:1611–1619 [CrossRef][PubMed]
    [Google Scholar]
  23. Tam V. H., Schilling A. N., Neshat S., Poole K., Melnick D. A., Coyle E. A.. 2005; Optimization of meropenem minimum concentration/MIC ratio to suppress in vitro resistance of Pseudomonas aeruginosa. Antimicrob Agents Chemother49:4920–4927 [CrossRef][PubMed]
    [Google Scholar]
  24. Tzouvelekis L. S., Markogiannakis A., Psichogiou M., Tassios P. T., Daikos G. L.. 2012; Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions. Clin Microbiol Rev25:682–707 [CrossRef][PubMed]
    [Google Scholar]
  25. Wiskirchen D. E., Nordmann P., Crandon J. L., Nicolau D. P.. 2013; Efficacy of humanized carbapenem exposures against New Delhi metallo-β-lactamase (NDM-1)-producing Enterobacteriaceae in a murine infection model. Antimicrob Agents Chemother57:3936–3940 [CrossRef][PubMed]
    [Google Scholar]
  26. Wiskirchen D. E., Nordmann P., Crandon J. L., Nicolau D. P.. 2014; In vivo efficacy of human simulated regimens of carbapenems and comparator agents against NDM-1-producing Enterobacteriaceae. Antimicrob Agents Chemother58:1671–1677 [CrossRef][PubMed]
    [Google Scholar]
  27. Zhou Q. T., He B., Zhang C., Zhai S. D., Liu Z. Y., Zhang J.. 2011; Pharmacokinetics and pharmacodynamics of meropenem in elderly Chinese with lower respiratory tract infections: population pharmacokinetics analysis using nonlinear mixed-effects modelling and clinical pharmacodynamics study. Drugs Aging28:903–912 [CrossRef][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.000214
Loading
/content/journal/jmm/10.1099/jmm.0.000214
Loading

Data & Media loading...

Most cited this month

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error